AfterRaise/Companies/City Therapeutics

City Therapeutics

City Therapeutics is a biopharmaceutical company developing RNA interference (RNAi)-based medicines. From its funding announcement.

$100M Series BRaised 4 months agoCambridge, USABiotech & PharmaUSA

In their own words

What City Therapeutics says it is doing

Work here? Claim your company profile

Public signal Described in the funding announcement as "biopharmaceutical company developing RNA interference (RNAi)-based medicines". Source

Why now

Where City Therapeutics is today

City Therapeutics announced a Series B round of $100M on 9 June 2026.

Latest round
Series B
Amount
$100M
Announced
9 June 2026
Headquarters
Cambridge, USA
Sector
Biotech & Pharma
Investors
Not stated
Also participating
Not stated
Relevant leadership
Not stated

Momentum AfterRaise intelligence

AfterRaise Score

55
Steady growth
0 funding signals in the last 90 days
Funding recency
18/40
announced within the last 6 months
Round scale
19/25
round size relative to the market
Funding stage
18/20
Series B
Funding cadence
0/15
one funding event tracked this year
Arriving with the signals layer
  • Hiring momentum Open roles and hiring pace
  • Market expansion New offices and new countries
  • Leadership Executive appointments
  • Product activity Launches and releases

Since the raise

What has happened since

  • 9 June 2026
    $100M Series B
    Investors not stated in the announcement.

Public signal The timeline currently holds funding events, because those are the signals AfterRaise observes today. Hiring, leadership, expansion and product events join it with the signals layer.

What may happen next

What this raise could create

AfterRaise intelligenceNot a statement of fact

What may happen next

  • Accelerated hiring across functions
  • Commercial scale-up
  • New market preparation
  • Leadership team completion

Opportunities this could create

  • Clinical operations
  • Regulatory affairs
  • CMC and manufacturing
  • Quality systems
  • Medical affairs

Based on the Biotech & Pharma sector and a Series B round. Not a statement of fact.

Early momentum1 connected signal
  • 9 June 2026$100M Series B announced

High momentum means several meaningful company changes have occurred in a short period. Signals here are funding events and the priorities the company stated; hiring, leadership and expansion detection join with the signals layer.

Open to

What City Therapeutics is open to

Not yet specified

City Therapeutics has not told AfterRaise which approaches it welcomes. Until it does, we do not assume. Offers to help are held and shown to the company, and the company decides whether to open a conversation.

Work here? Set your preferences

Opportunities

Ways to work with City Therapeutics

No open opportunities listed

Jobs, projects, partnerships, advisory and supplier needs appear here once the company has claimed its page and published them, and any role we read from its own job board appears automatically.

Work here? Open the first one

Helpful contributors

People who have contributed here

Nobody yet

When someone offers help and the company says it was useful, they appear here. Reputation on AfterRaise is built from contributions the company confirmed, not from follower counts.

Do you work at City Therapeutics?

Claim your company profile.

This page was created from publicly available information. A verified representative corrects the record, says what the company is building next and chooses which conversations it welcomes.

What we do not have yet: your website, what the round is for, in your words, the roles and projects you have open and who leads the team. Claiming the page is how you fill those in.

Someone else requesting access does not give them ownership. Every representative is verified by a person before access is granted.

Maintaining your own company profile is free. A founder, CEO or authorised senior colleague can represent the company.

Also moving

Other Biotech & Pharma companies

See the sector